Showing results (131-140 of 153) with videos related to

Sort By:
Pageof 16
Plos One|March 29, 2016
Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C DiseaseElena-Raluca Nicoli, Nada Al Eisa, Celine V M Cluzeau, et al.
Molecular Pharmacology|June 9, 2019
Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile TransportersTristan M Sissung, Phoebe A Huang, Ralph J Hauke, et al.
Blood Advances|May 27, 2026
Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 studyNoa G Holtzman, Annie Im, Lauren M Curtis, et al.
Journal for Immunotherapy of Cancer|November 20, 2021
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumorsKevin Conlon, Dionysios C Watson, Thomas A Waldmann, et al.
Molecular Cancer Research : MCR|April 9, 2017
Differential Expression of OATP1B3 Mediates Unconjugated Testosterone InfluxTristan M Sissung, Ariel M Ley, Jonathan D Strope, et al.
International Journal of Cancer|May 20, 2016
Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancerA G Duffy, O V Makarova-Rusher, S V Ulahannan, et al.
Journal of Neuro-Oncology|October 11, 2020
A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomasSean J Hipp, Stewart Goldman, Aradhana Kaushal, et al.
Nature Communications|July 15, 2018
Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastasesBrunilde Gril, Anurag N Paranjape, Stephan Woditschka, et al.
Cancers|August 26, 2023
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric RhabdomyosarcomaJerry T Wu, Adam Cheuk, Kristine Isanogle, et al.
Blood|September 25, 2020
A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host diseaseLauren M Curtis, Alen Ostojic, David J Venzon, et al.
Pageof 16